Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| J2K-MC-JZKA | Other Identifier | Eli Lilly and Company | |
| 2019-003070-53 | EudraCT Number |
Not provided
Not provided
Not provided
The study was terminated due to an unexpected toxicity finding.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LY3499446 Phase 1 Cohort A1 High Dose | Experimental | Participants received high dose LY3499446 as oral monotherapy twice daily (BID) in 21-day cycles. |
|
| LY3499446 Phase 1 Cohort AO Mid Dose | Experimental | Participant received mid dose LY3499446 as oral monotherapy once every other day (QOD) in 21-day cycles. |
|
| LY3499446 Phase 1 Cohort A-2 Low Dose | Experimental | Participants received low dose LY3499446 as oral monotherapy once daily (QD) in 21-Day cycles. |
|
| LY3499446 + Combination Drugs Phase 1 | Experimental | LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV). This trial was terminated prior to initiation of combination therapy cohorts. |
|
| LY3499446 Monotherapy + Combination Drugs Phase 2 | Experimental | LY3499446 as oral monotherapy and LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV). The trial was terminated prior to initiation of Phase 2 of this study. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LY3499446 | Drug | Administered orally |
|
| Measure | Description | Time Frame |
|---|---|---|
| Phase 1: Number or Participants With Dose Limiting Toxicities (DLTs) | DLT is defined as an event that is clinically significant and not clearly related to disease progression or intercurrent illness that occurred within the DLT observation period of the Cycle 1 timeframe. | Cycle 1 (21 Day Cycle) |
| Phase 2: Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR) in Colorectal Cancer (CRC) Cohorts and Other Tumors Cohort | ORR is defined as percentage of participants who achieved a CR or PR out of all the participants treated. Tumor responses were measured and record using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST) v1.1 guidelines. CR is defined as the disappearance of all targeted and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions. | Baseline through Measured Progressive Disease |
| Phase 2: Progression-Free Survival (PFS) Non-Small Lung Cancer (NSCLC Cohorts) | PFS was defined as the time from study enrollment (for non-randomized cohorts)/ the time from randomization (for randomized cohorts) to the first observation of progressive disease (PD) or death without documented disease progression per RECIST V1.1 criteria. | Baseline to Objective Progression or Death Due to Any Cause |
| Measure | Description | Time Frame |
|---|---|---|
| Phase 1: Pharmacokinetics (PK): Average Concentration of LY3499446 | Average concentration after the first dose of LY3499446. | Cycle 1 Day 1: Predose, 0.5, 1, 1.5, 2, 3, 4, 8, 24 hours post-dose |
| Phase 1: PK: Average Concentration at Steady State of LY3499446 in Combination With Abemaciclib |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Indiana Univ Melvin & Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | United States | ||
| Memorial Sloan Kettering Cancer Center |
Not provided
| Label | URL |
|---|---|
| A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | View source |
Not provided
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
A participant was identified as having completed the study if the participant was observed until event of progressive disease (PD) or death, or the participant had discontinued study treatment and is in follow up at the time of the final analysis.
The study was terminated due to an unexpected toxicity finding.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | LY3499446 Phase 1 Cohort A1 (High Dose) | Participants received high dose LY3499446 as oral monotherapy twice daily (BID) in 21-day cycles. |
| FG001 | LY3499446 Phase 1 Cohort AO (Mid Dose) |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jan 21, 2020 | Oct 5, 2021 |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Docetaxel Phase 2 | Active Comparator | Docetaxel IV infusion. The trial was terminated prior to initiation of Phase 2 of this study. |
|
| Abemaciclib | Drug | Administered orally |
|
|
| Cetuximab | Drug | Administered IV |
|
| Erlotinib | Drug | Administered orally |
|
| Docetaxel | Drug | Administered IV |
|
PK: Average Concentration at Steady State of LY3499446 in Combination with Abemaciclib |
| Predose Cycle 1 Day 1 through Cycle 3 Day 1 (21 Day Cycles) |
| Phase 1: PK: Average Concentration at Steady State of LY3499446 in Combination With Cetuximab | PK: Average Concentration at Steady State of LY3499446 in Combination with Cetuximab | Predose Cycle 1 Day 1 through Cycle 3 Day 1 (21 Day Cycles) |
| Phase 1: PK: Average Concentration at Steady State of LY3499446 in Combination With Erlotinib | PK: Average Concentration at Steady State of LY3499446 in Combination with Erlotinib | Predose Cycle 1 Day 1 through Cycle 3 Day 1 (21 Day Cycles) |
| Phase 1: ORR: Percentage of Participants Who Achieve CR or PR | ORR is defined as percentage of participants who achieved a CR or PR out of all the participants treated. Tumor responses were measured and record using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST) v1.1 guidelines. CR is defined as the disappearance of all targeted and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions. | Baseline through Measured Progressive Disease (Up to 11 Months) |
| Phase 1: PFS | PFS was defined as the time from study enrollment (for non-randomized cohorts)/ the time from randomization (for randomized cohorts) to the first observation of progressive disease (PD) overall response or death without documented disease progression per RECIST V1.1 criteria. | Baseline to Objective Progression or Death Due to Any Cause (Up to 11 Months) |
| Phase 1: Duration of Response (DoR) | DoR was defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST v1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. | Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Up to 11 Months) |
| Phase 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and SD | DCR was defined as the percentage of participants who achieved a best overall response (BOR) of confirmed CR, confirmed PR, or SD out of all participants treatment. Best response is determined from a sequence of responses assessed. Two determinations of PR or better before progression, but not qualifying for a CR, are required for a best response of PR. CR is defined as the disappearance of all targeted and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions. | Baseline through Measured Progressive Disease (Up to 11 Months) |
| Middletown |
| New Jersey |
| 07748 |
| United States |
| Memorial Sloan Kettering Cancer Center | Harrison | New York | 10604 | United States |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10022 | United States |
| St Vincent's Hospital | Darlinghurst | New South Wales | 2010 | Australia |
| Linear Clinical Research Ltd | Nedlands | Western Australia | 6009 | Australia |
Participant received mid dose LY3499446 as oral monotherapy once every other day (QOD) in 21-day cycles.
| FG002 | LY3499446 Phase 1 Cohort A-2 (Low Dose) | Participants received low dose LY 3499446 as oral monotherapy once daily (QD) in 21-day cycles. |
| FG003 | LY3499446 + Combination Drug Phase 1 | LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV). The trial was terminated prior to initiation of this portion. |
| FG004 | LY3499446 Monotherapy + Combination Drug Phase 2 | LY3499446 monotherapy orally. LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV). The trial was terminated prior to initiation of this portion. |
| FG005 | Docetaxel Phase 2 | Docetaxel IV infusion. The trial was terminated prior to initiation of this portion. |
| Received at Least One Dose of Study Drug |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
All participants who received at least one dose of study drug
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | LY3499446 Phase 1 Cohort A1 (High Dose) | Participants received high dose LY3499446 as oral monotherapy BID in 21-day cycles. |
| BG001 | LY3499446 Phase 1 Cohort AO (Mid Dose) | Participant received mid dose LY3499446 as oral monotherapy once QOD in 21-day cycles. |
| BG002 | LY3499446 Phase 1 Cohort A-2 (Low Dose) | Participants received low dose LY 3499446 as oral monotherapy once QD in 21-day cycles. |
| BG003 | LY3499446 + Combination Drug Phase 1 | LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV). The trial was terminated prior to initiation of this portion. |
| BG004 | LY3499446 Monotherapy + Combination Drug Phase 2 | LY3499446 monotherapy orally. LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV). The trial was terminated prior to initiation of this portion. |
| BG005 | Docetaxel Phase 2 | Docetaxel IV infusion. The trial was terminated prior to initiation of this portion. |
| BG006 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants | No |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants | No |
| |||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants | No |
| |||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants | No |
| |||||||||||||||
| Region of Enrollment | Count of Participants | Participants | No |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Phase 1: Number or Participants With Dose Limiting Toxicities (DLTs) | DLT is defined as an event that is clinically significant and not clearly related to disease progression or intercurrent illness that occurred within the DLT observation period of the Cycle 1 timeframe. | All participants who received at least one dose of study drug and had a dose limiting toxicity. | Posted | Count of Participants | Participants | No | Cycle 1 (21 Day Cycle) |
|
|
| |||||||||||||||||||||||||||||||
| Primary | Phase 2: Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR) in Colorectal Cancer (CRC) Cohorts and Other Tumors Cohort | ORR is defined as percentage of participants who achieved a CR or PR out of all the participants treated. Tumor responses were measured and record using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST) v1.1 guidelines. CR is defined as the disappearance of all targeted and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions. | Zero participants were analyzed due to early termination of study. | Posted | Baseline through Measured Progressive Disease |
|
| |||||||||||||||||||||||||||||||||||
| Primary | Phase 2: Progression-Free Survival (PFS) Non-Small Lung Cancer (NSCLC Cohorts) | PFS was defined as the time from study enrollment (for non-randomized cohorts)/ the time from randomization (for randomized cohorts) to the first observation of progressive disease (PD) or death without documented disease progression per RECIST V1.1 criteria. | Zero participants were analyzed due to early termination of study. | Posted | Baseline to Objective Progression or Death Due to Any Cause |
|
| |||||||||||||||||||||||||||||||||||
| Secondary | Phase 1: Pharmacokinetics (PK): Average Concentration of LY3499446 | Average concentration after the first dose of LY3499446. | All participants who have received at least one dose of study drug and had evaluable PK. | Posted | Geometric Mean | Geometric Coefficient of Variation | nanograms per milliliter (ng/mL) | Cycle 1 Day 1: Predose, 0.5, 1, 1.5, 2, 3, 4, 8, 24 hours post-dose |
|
| ||||||||||||||||||||||||||||||||
| Secondary | Phase 1: PK: Average Concentration at Steady State of LY3499446 in Combination With Abemaciclib | PK: Average Concentration at Steady State of LY3499446 in Combination with Abemaciclib | Zero participants were analyzed due to early termination of study. | Posted | Predose Cycle 1 Day 1 through Cycle 3 Day 1 (21 Day Cycles) |
|
| |||||||||||||||||||||||||||||||||||
| Secondary | Phase 1: PK: Average Concentration at Steady State of LY3499446 in Combination With Cetuximab | PK: Average Concentration at Steady State of LY3499446 in Combination with Cetuximab | Zero participants were analyzed due to early termination of study. | Posted | Predose Cycle 1 Day 1 through Cycle 3 Day 1 (21 Day Cycles) |
|
| |||||||||||||||||||||||||||||||||||
| Secondary | Phase 1: PK: Average Concentration at Steady State of LY3499446 in Combination With Erlotinib | PK: Average Concentration at Steady State of LY3499446 in Combination with Erlotinib | Zero participants were analyzed due to early termination of study. | Posted | Predose Cycle 1 Day 1 through Cycle 3 Day 1 (21 Day Cycles) |
|
| |||||||||||||||||||||||||||||||||||
| Secondary | Phase 1: ORR: Percentage of Participants Who Achieve CR or PR | ORR is defined as percentage of participants who achieved a CR or PR out of all the participants treated. Tumor responses were measured and record using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST) v1.1 guidelines. CR is defined as the disappearance of all targeted and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions. | Zero participants were analyzed due to early termination of study. | Posted | Baseline through Measured Progressive Disease (Up to 11 Months) |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Phase 1: PFS | PFS was defined as the time from study enrollment (for non-randomized cohorts)/ the time from randomization (for randomized cohorts) to the first observation of progressive disease (PD) overall response or death without documented disease progression per RECIST V1.1 criteria. | Zero participants were analyzed due to early termination of study. | Posted | Baseline to Objective Progression or Death Due to Any Cause (Up to 11 Months) |
|
| |||||||||||||||||||||||||||||||||||
| Secondary | Phase 1: Duration of Response (DoR) | DoR was defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST v1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence. | Zero participants were analyzed due to early termination of study. | Posted | Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Up to 11 Months) |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Phase 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and SD | DCR was defined as the percentage of participants who achieved a best overall response (BOR) of confirmed CR, confirmed PR, or SD out of all participants treatment. Best response is determined from a sequence of responses assessed. Two determinations of PR or better before progression, but not qualifying for a CR, are required for a best response of PR. CR is defined as the disappearance of all targeted and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions. | Zero participants were analyzed due to early termination of study. | Posted | Baseline through Measured Progressive Disease (Up to 11 Months) |
|
Baseline up to 11 months
All participants who received at least one dose of study drug.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | LY3499446 Phase 1 Cohort A1 (High Dose) | Participants received high dose LY3499446 as oral monotherapy twice daily (BID) in 21-day cycles. | 1 | 2 | 0 | 2 | 2 | 2 |
| EG001 | LY3499446 Phase 1 Cohort AO (Mid Dose) | Participant received mid dose LY3499446 as oral monotherapy once every other day (QOD) in 21-day cycles. | 0 | 1 | 0 | 1 | 1 | 1 |
| EG002 | LY3499446 Phase 1 Cohort A-2 (Low Dose) | Participants received low dose LY3499446 as monotherapy orally once QD in 21-day cycles. | 1 | 2 | 1 | 2 | 2 | 2 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pyrexia | General disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Hypoxia | Respiratory, thoracic and mediastinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 23.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 22.1 | Systematic Assessment |
| |
| Haemolysis | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Leukocytosis | Blood and lymphatic system disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Cardiac arrest | Cardiac disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Palpitations | Cardiac disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
| |
| Blood bilirubin increased | Investigations | MedDRA 22.1 | Systematic Assessment |
| |
| Haptoglobin decreased | Investigations | MedDRA 23.1 | Systematic Assessment |
| |
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Flank pain | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Amnesia | Nervous system disorders | MedDRA 22.1 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 22.1 | Systematic Assessment |
| |
| Dysgeusia | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 22.1 | Systematic Assessment |
| |
| Paraesthesia | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 23.1 | Systematic Assessment |
| |
| Skin hyperpigmentation | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment |
|
The study was terminated due to an unexpected toxicity finding.
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Chief Medical Officer | Eli Lilly and Company | 800-545-5979 | ClinicalTrials.gov@lilly.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Feb 4, 2020 | Oct 5, 2021 | SAP_001.pdf |
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| D015179 | Colorectal Neoplasms |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000590451 | abemaciclib |
| D000068818 | Cetuximab |
| D000069347 | Erlotinib Hydrochloride |
| D000077143 | Docetaxel |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D011799 | Quinazolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D043823 | Taxoids |
| D043822 | Cyclodecanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D004224 | Diterpenes |
| D013729 | Terpenes |
Not provided
Not provided
| Between 18 and 65 years |
|
| >=65 years |
|
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Australia |
|
|
|
|
|
| Participants |
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
Participants received low dose LY3499446 as oral monotherapy once QD in 21-day cycles.
|